NCT05393427View on ClinicalTrials.gov

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Locally Advanced or Metastatic Urinary TumorsOther Solid Tumors
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion

Trial Locations (4)

100142

Beijing Cancer Hospital, Beijing

Unknown

Peking University First Hospital, Beijing

Chongqing University Cancer Hospital, Chongqing

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05393427 - A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors | Biotech Hunter | Biotech Hunter